pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG
Plasmacytoid dendritic cells (pDCs) express high levels of the toll-like receptors (TLRs) TLR7 and TLR9. In response to TLR7 and TLR9 ligands, pDCs are primary producers of type I interferons. Our previous study demonstrated that pDCs activated by the TLR7 ligand imiquimod (IMQ) and the TLR9 ligand...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2019/1749803 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549446474268672 |
|---|---|
| author | Jing Wu Shuang Li Tete Li Xinping Lv Mingyou Zhang Guoxia Zang Chong Qi Yong-Jun Liu Liang Xu Jingtao Chen |
| author_facet | Jing Wu Shuang Li Tete Li Xinping Lv Mingyou Zhang Guoxia Zang Chong Qi Yong-Jun Liu Liang Xu Jingtao Chen |
| author_sort | Jing Wu |
| collection | DOAJ |
| description | Plasmacytoid dendritic cells (pDCs) express high levels of the toll-like receptors (TLRs) TLR7 and TLR9. In response to TLR7 and TLR9 ligands, pDCs are primary producers of type I interferons. Our previous study demonstrated that pDCs activated by the TLR7 ligand imiquimod (IMQ) and the TLR9 ligand CpG A can kill breast cancer cells in vitro and inhibit tumor growth in vivo. Moreover, we observed a distinctive morphological, phenotypic change in pDCs after activation by IMQ and CpG A. However, the effect of other TLR7 and TLR9 ligands on pDCs remains less understood. In this study, we treat pDCs with the TLR7 ligand IMQ, TLR7/8 ligands (CL097 and CL075), and three TLR9 ligands (different types of CpGs). The size of pDCs increased significantly after activation by TLR7, or TLR7/8 ligands. TLR7, TLR7/8, and TLR9 ligands similarly modulated cytokine release, as well as protein expression of pDC markers, costimulatory molecules, and cytotoxic molecules. Interestingly, TLR7/8 ligands, especially CL097, induced stronger responses. These results are relevant to the further study of the role and mechanism of pDC-induced antitumor effects and may aid in the development of a new strategy for future tumor immunotherapy. |
| format | Article |
| id | doaj-art-75d52c4a414a4013a2f8bce49ae63f11 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-75d52c4a414a4013a2f8bce49ae63f112025-02-03T06:11:17ZengWileyJournal of Immunology Research2314-88612314-71562019-01-01201910.1155/2019/17498031749803pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpGJing Wu0Shuang Li1Tete Li2Xinping Lv3Mingyou Zhang4Guoxia Zang5Chong Qi6Yong-Jun Liu7Liang Xu8Jingtao Chen9Institute of Translational Medicine, The First Hospital, Jilin University, Changchun 130061, ChinaInstitute of Translational Medicine, The First Hospital, Jilin University, Changchun 130061, ChinaInstitute of Translational Medicine, The First Hospital, Jilin University, Changchun 130061, ChinaInstitute of Translational Medicine, The First Hospital, Jilin University, Changchun 130061, ChinaDepartment of Cardiovascular Center, The First Hospital, Jilin University, Changchun 130031, ChinaInstitute of Translational Medicine, The First Hospital, Jilin University, Changchun 130061, ChinaInstitute of Translational Medicine, The First Hospital, Jilin University, Changchun 130061, ChinaInstitute of Translational Medicine, The First Hospital, Jilin University, Changchun 130061, ChinaState key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology, Beijing 100850, ChinaInstitute of Translational Medicine, The First Hospital, Jilin University, Changchun 130061, ChinaPlasmacytoid dendritic cells (pDCs) express high levels of the toll-like receptors (TLRs) TLR7 and TLR9. In response to TLR7 and TLR9 ligands, pDCs are primary producers of type I interferons. Our previous study demonstrated that pDCs activated by the TLR7 ligand imiquimod (IMQ) and the TLR9 ligand CpG A can kill breast cancer cells in vitro and inhibit tumor growth in vivo. Moreover, we observed a distinctive morphological, phenotypic change in pDCs after activation by IMQ and CpG A. However, the effect of other TLR7 and TLR9 ligands on pDCs remains less understood. In this study, we treat pDCs with the TLR7 ligand IMQ, TLR7/8 ligands (CL097 and CL075), and three TLR9 ligands (different types of CpGs). The size of pDCs increased significantly after activation by TLR7, or TLR7/8 ligands. TLR7, TLR7/8, and TLR9 ligands similarly modulated cytokine release, as well as protein expression of pDC markers, costimulatory molecules, and cytotoxic molecules. Interestingly, TLR7/8 ligands, especially CL097, induced stronger responses. These results are relevant to the further study of the role and mechanism of pDC-induced antitumor effects and may aid in the development of a new strategy for future tumor immunotherapy.http://dx.doi.org/10.1155/2019/1749803 |
| spellingShingle | Jing Wu Shuang Li Tete Li Xinping Lv Mingyou Zhang Guoxia Zang Chong Qi Yong-Jun Liu Liang Xu Jingtao Chen pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG Journal of Immunology Research |
| title | pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG |
| title_full | pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG |
| title_fullStr | pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG |
| title_full_unstemmed | pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG |
| title_short | pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG |
| title_sort | pdc activation by tlr7 8 ligand cl097 compared to tlr7 ligand imq or tlr9 ligand cpg |
| url | http://dx.doi.org/10.1155/2019/1749803 |
| work_keys_str_mv | AT jingwu pdcactivationbytlr78ligandcl097comparedtotlr7ligandimqortlr9ligandcpg AT shuangli pdcactivationbytlr78ligandcl097comparedtotlr7ligandimqortlr9ligandcpg AT teteli pdcactivationbytlr78ligandcl097comparedtotlr7ligandimqortlr9ligandcpg AT xinpinglv pdcactivationbytlr78ligandcl097comparedtotlr7ligandimqortlr9ligandcpg AT mingyouzhang pdcactivationbytlr78ligandcl097comparedtotlr7ligandimqortlr9ligandcpg AT guoxiazang pdcactivationbytlr78ligandcl097comparedtotlr7ligandimqortlr9ligandcpg AT chongqi pdcactivationbytlr78ligandcl097comparedtotlr7ligandimqortlr9ligandcpg AT yongjunliu pdcactivationbytlr78ligandcl097comparedtotlr7ligandimqortlr9ligandcpg AT liangxu pdcactivationbytlr78ligandcl097comparedtotlr7ligandimqortlr9ligandcpg AT jingtaochen pdcactivationbytlr78ligandcl097comparedtotlr7ligandimqortlr9ligandcpg |